Imugene Limited (AU:IMU) has released an update.
Imugene Limited, a clinical stage immuno-oncology company, has just secured a significant patent grant in China for its CF33 oncolytic virotherapy, which includes VAXINIA and CHECKvacc, offering protection until 2037. This development represents a major milestone as the patent covers the method of composition and method of use, and with China being a major player in the Asian pharmaceutical market, it could have substantial implications for cancer treatment and the company’s market position.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
